Congress Asset Management Co. Sells 429,504 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Congress Asset Management Co. lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 99.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,361 shares of the medical research company’s stock after selling 429,504 shares during the period. Congress Asset Management Co.’s holdings in Charles River Laboratories International were worth $805,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CRL. V Square Quantitative Management LLC grew its holdings in shares of Charles River Laboratories International by 12.6% during the fourth quarter. V Square Quantitative Management LLC now owns 1,084 shares of the medical research company’s stock worth $200,000 after buying an additional 121 shares in the last quarter. Vontobel Holding Ltd. bought a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $335,000. Asset Management One Co. Ltd. grew its stake in shares of Charles River Laboratories International by 1.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 18,918 shares of the medical research company’s stock worth $3,522,000 after acquiring an additional 315 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Finally, North Growth Management Ltd. lifted its position in shares of Charles River Laboratories International by 18.2% in the fourth quarter. North Growth Management Ltd. now owns 39,000 shares of the medical research company’s stock worth $7,168,000 after purchasing an additional 6,000 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CRL shares. Barclays lowered their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. cut their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Monday, February 3rd. Finally, The Goldman Sachs Group dropped their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $197.64.

Charles River Laboratories International Stock Up 1.7 %

Charles River Laboratories International stock opened at $154.63 on Wednesday. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The stock has a market cap of $7.91 billion, a P/E ratio of 19.35, a P/E/G ratio of 6.47 and a beta of 1.37. The company’s 50-day moving average price is $174.59 and its two-hundred day moving average price is $189.16. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).